Literature DB >> 2823368

Rheumatoid arthritis in Greece. Manifestations in different age groups.

A P Andonopoulos1, V Galanopoulou, A A Drosos, H M Moutsopoulos.   

Abstract

A high frequency of anti-Ro (SSA) circulating antibodies and lack of HLA-DR4 association described recently in Greek rheumatoid arthritis (RA) patients, prompted us to study their clinical and laboratory picture and compare it with that described in the literature. One hundred and ninety seven patients with definite or classical RA were divided into three groups A, B, and C with age at disease onset below 39, between 40 and 59, and above 60 years respectively. Disease duration below 5 and above 5 years resulted in further division of each group into subgroups 1 and 2. With few exceptions, there were no significant differences between the groups in terms of maximal articular index, lymphadenopathy, splenomegaly, hepatomegaly, frequency of rheumatoid nodules and lowest hematocrit, highest erythrocyte sedimentation rate, and C-reactive protein values. The presence of rheumatoid factor, antinuclear antibodies, cryoglobulins, and elevated levels of globulins, C3 and C4 in patients' sera were not significantly different among the groups. A statistically significant radiologic deterioration was observed with disease duration, common in all groups. Diffuse interstitial lung disease was the most common pulmonary abnormality noted. There were no differences between the groups. Penicillamine toxicity was independent of age and disease duration. This study suggests that the clinical picture of RA in Greece is similar to that in other populations and that there are no significant differences in general among its age groups.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2823368     DOI: 10.1007/BF00270461

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  24 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  The clinical features of rheumatoid arthritis. Prognostic indices.

Authors:  C RAGAN
Journal:  JAMA       Date:  1962-08-25       Impact factor: 56.272

3.  Rheumatoid arthritis in the aged.

Authors:  R L CECIL; W H KAMMERER
Journal:  Am J Med       Date:  1951-04       Impact factor: 4.965

Review 4.  Pulmonary involvement in the collagen vascular diseases.

Authors:  G W Hunninghake; A S Fauci
Journal:  Am Rev Respir Dis       Date:  1979-03

5.  Rheumatoid arthritis in the aged.

Authors:  G E Ehrlich; W A Katz; S H Cohen
Journal:  Geriatrics       Date:  1970-02

6.  Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases.

Authors:  D G Scott; P A Bacon; C R Tribe
Journal:  Medicine (Baltimore)       Date:  1981-07       Impact factor: 1.889

7.  An immunogenetic study of older age onset rheumatoid arthritis.

Authors:  R Terkeltaub; F Décary; J Esdaile
Journal:  J Rheumatol       Date:  1984-04       Impact factor: 4.666

8.  Benign rheumatoid arthritis of the aged.

Authors:  A B Corrigan; R G Robinson; T R Terenty; J B Dick-Smith; D Walters
Journal:  Br Med J       Date:  1974-03-09

9.  Anti-Ro(SSA) positive rheumatoid arthritis (RA): a clinicoserological group of patients with high incidence of D-penicillamine side effects.

Authors:  H M Moutsopoulos; F N Skopouli; A K Sarras; C Tsampoulas; A K Mavridis; S H Constantopoulos; P J Maddison
Journal:  Ann Rheum Dis       Date:  1985-04       Impact factor: 19.103

10.  Prognosis in rheumatoid arthritis. A longitudinal study of newly diagnosed younger adult patients.

Authors:  S L Feigenbaum; A T Masi; S B Kaplan
Journal:  Am J Med       Date:  1979-03       Impact factor: 4.965

View more
  1 in total

1.  D-penicillamine induced myasthenia gravis in rheumatoid arthritis: an unpredictable common occurrence?

Authors:  A P Andonopoulos; E Terzis; E Tsibri; C A Papasteriades; T Papapetropoulos
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.